Product Description
SGT-53 is a complex composed of a wild type p53 gene (plasmid DNA) encapsulated in a liposome that is targeted to tumor cells by means of an anti-transferrin receptor single-chain antibody fragment (TfRscFv) attached to the outside of the liposome. Pre-clinical studies have indicated that SGT-53 could sensitize tumors to the effects of radiation/chemotherapy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00470613)
Mechanisms of Action: Gene Therapy
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Glioblastoma|Pancreatic Cancer
Phase 1: Oncology Solid Tumor Unspecified|Triple Negative Breast Cancer|Rhabdomyosarcoma|Inflammatory Breast Cancer|Liver Cancer|Oncology Unspecified|Bone Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SGT53-00-1 | P1 |
Unknown status |
Oncology Unspecified |
2023-12-01 |
27% |
| SGT53-02-1 | P2 |
Unknown status |
Pancreatic Cancer |
2022-12-01 |
57% |
| SGT53-01-2 | P1 |
Suspended |
Rhabdomyosarcoma|Liver Cancer|Bone Cancer |
2022-12-01 |
43% |
| NU 19B07 | P1 |
Withdrawn |
Triple Negative Breast Cancer|Inflammatory Breast Cancer |
2022-11-10 |